Raquel Perez-Lopez

Principal Investigator Radiomics Group at Vall d'Hebron Institute of Oncology (VHIO)

Raquel Perez-Lopez's work experience includes being a Principal Investigator in the Radiomics Group at Vall d´Hebron Institute of Oncology (VHIO) since 2017. Prior to that, they worked as a Researcher PHD Student at UAB - Universitat Autònoma de Barcelona starting in 2014. Raquel was also a Clinical Research Fellow at The Institute of Cancer Research starting in 2013. Additionally, they were a Musculoskeletal Imaging Consultant at Consorci Sanitari Integral (CSI) from 2012 to 2013. Raquel also had an Honorary Fellowship at Barts Health NHS Trust in 2011. Raquel began their career as a former SpR at Hospital Universitari de Bellvitge.

Raquel Perez-Lopez earned a Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from Universitat de Barcelona in the field of Medicine between 2000 and 2006. Later, they pursued a Master of Science (MSc) degree in Master in Clinical Research from the same university from 2010 to 2011.

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Vall d'Hebron Institute of Oncology (VHIO)

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.


Industries

Headquarters

Spain

Employees

201-500

Links